MARK CARLE CONNELLY
Pilots at Nottingham Way, Gardenville, PA

2011030, Dec 8, 2011

Jun 8, 2011

13/155687

Galla Chandra Rao - Princeton Junction NJ, US
Mark C. Connelly - Doylestown PA, US

C12Q 1/68, G01N 33/574, C12Q 1/06

435 614, 435 39, 435 723

The present invention provides an automated method for capturing and detecting circulating melanoma cells (CMC's) in the blood of patients with melanoma. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy.

7901950, Mar 8, 2011

Feb 2, 2007

11/701763

Mark Carle Connelly - Doylestown PA, US
Gerald V. Doyle - Radnor PA, US
Galla Chandra Rao - Princeton Junction NJ, US
Leon W. M. M. Terstappen - Huntingdon Valley PA, US

Veridex, LLC - Raritan NJ

G01N 33/553, G01N 33/00, G01N 1/00, G01N 1/18

436526, 435 72, 435 724, 435372, 4352872, 436518, 436523, 436536, 436538, 436 10, 436 17, 436 18, 436 63, 436172, 436176, 436177, 422 73, 422 8205, 422101

Elevated number of Circulating Endothelial Cells (CEC) have been implicated in disease conditions associated with the formation or destruction of blood vessels such as acute coronary syndrome, thrombocytopenic purpura, sickle cell disease, sepsis, lupus, nephrotic syndromes, rejection of organ transplants, surgical trauma and cancer. This invention provides a method for assessing the levels of CEC which vary between different studies using a sensitive enrichment, imaging, and enumberation analysis. CD146 is one of the most specific endothelium-associated cell-surface antigens which can be used in image cytometry. CEC analysis provides an essential tool in prognostic/diagnostic evaluation in the clinic.

2012020, Aug 9, 2012

Apr 16, 2008

12/450846

Mark Carle Connelly - Doylestown PA, US
Frank A.W. Coumans - Philadelphia PA, US
Jimmy Page - McHenry IL, US
Galla Chandra Rao - Junction NJ, US
Joseph Jollick, JR. - Athens OH, US

G01N 21/17

435 5

A novel cytometer system, methods and algorithms which provide a rugged, affordable and easy-to-use device in remote locations. All cells in a biological sample are fluorescently labeled, with target cells also magnetically labeled. Non-magnetically labeled cells are imaged for viability. Labeled sample is placed between two wedge-shaped magnets to selectively move the magnetically labeled cells for observation. A LED illuminates the cells and a CCO camera captures the images of the fluorescent light emitted by the target cells. Image analysis performed with a novel algorithm provides a cell count that can be related to the target cell concentration of the original sample.

7674632, Mar 9, 2010

Nov 15, 2002

10/295118

Mark Carle Connelly - Doylestown PA, US
Mark Kopnitsky - Easton PA, US

Zeus Scientific, Inc - Branchburg NJ

G01N 33/553, G01N 33/53

436525, 436518, 436526, 436 8, 435 72, 435 77, 435 78

A method and composition for detecting and measuring analytes, such as antibodies, which are capable of binding with certain binding partners such as antigens. A homogenous assay is performed in the presence of free unbound antibodies. Such a homogeneous assay testing for specific antibodies is herein possible by defining of test subsets of microparticles having specific antigens thereon which are capable of binding with specific target antibodies. The microparticle suspension also includes at least two calibration subsets of microparticles having a binding partner thereon with at least two known levels of concentration which is capable of binding with human antibodies for the purpose of assay calibration. A verification subset of microparticles is included with another binding partner thereon at a known concentration, capable of binding with anti-human antibodies. This suspension is incubated with a human sample and then is incubated with a tagging component.

2012009, Apr 19, 2012

Oct 13, 2011

13/272769

Galla Chandra Rao - Princeton Junction NJ, US
Mark Carle Connelly - Doylestown PA, US

C12Q 1/70, G01N 33/554, G01N 33/566

435 5, 435 72, 435 721, 435 732

A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric or image cytometry to detect, enumerate and characterize carcinoma cells in the blood. The present invention incorporates the conjugation of different antibodies to the same ferrofluid. This has the effect of making the ferrofluid polyspecific with respect to the antigens that the ferrofluid will bind. The multiple antibodies present on the same ferrofluid do not appear to block or otherwise interfere with each other. Such ferrofluids have the highly desirable effect of being able to bind specifically to more than one type of cell. The assay is especially useful to enable the capture of CTCs that have low EpCAM expression, but high expression of other tumor markers; Accordingly, the assay facilitates the biological characterization and staging of carcinoma cells.

5597688, Jan 28, 1997

Jun 6, 1995

8/467799

Mark C. Connelly - Doylestown PA
Utpal R. Chakraborty - Flemington NJ
Houston G. Brooks - Somerset NJ

Ortho Diagnostic Systems Inc. - Raritan NJ

C12Q 170, G01N 3353, G01N 33569

435 5

The present invention provides a novel cellular fixative composition and method of cellular fixing and cellular analysis wherein cells may be fixed for further analysis without destroying the cell's surface markers, cellular morphology, and the cell's light scattering properties. Treatment of cells with the fixative as described herein also allows antibodies or. other desired components to enter the cell through the cellular membrane, without allowing important contents of the cell to escape. As an added benefit, the fixative composition of the invention may also kill or at least inactivate or reduce the activity of deadly virus contained in the cell. In its broadest aspect, the presently claimed fixative composition comprises at least three components, and in more preferred embodiments, four components. In a particularly preferred embodiment, the fixative composition described herein comprises at least one compound suitable for increasing the permeability of a cellular membrane, at least one compound that facilitates transportation of components across cellular membranes, at least one detergent, and at least one compound having the structure: R. sub. 1 R. sub. 2 R. sub. 3 R. sub. 4 R. sub. 5 --Ar--X.

2013015, Jun 20, 2013

Jul 6, 2012

13/543661

Eric Topol - La Jolla CA, US
Samir Damani - San Diego CA, US
Mark Connelly - Doylestown PA, US
Galla Chandra Rao - Princeton Junction NJ, US

Veridex, LLC - Raritan NJ
Scripps Health - San Diego CA

C12Q 1/04

4352872, 4352887

Compositions, systems, and methods comprising circulating endothelial cells (CECs) are provided. The compositions described herein utilize isolated CECs, including compositions in a form that allows analysis of the CECs. The systems described herein utilize isolated CECs and an analytical tool or an output from an analytical tool. The methods described herein are related to the use of isolated CECs and analytical tools for providing information, to a health care provider or the CEC donor, that is relevant to the cardiovascular health of the CEC donor. Thus, the compositions, systems and methods described herein involve both a transformation (e.g., non-isolated CECs to isolated CECs, or isolated CECs to analyzed CECs) and a machine (e.g., isolation tools and analytical tools).

2010002, Feb 4, 2010

May 29, 2007

12/303243

Antonio Gualberto - East Greenwich RI, US
Maria Luisa Paccagnella - Noank CT, US
Carrie L. Melvin - Ledyard CT, US
Madeline I. Repollet - Fort Washingtion PA, US
David Chianese - Ardmore PA, US
Mark Carle Connelly - Doylestown PA, US
Leonardus Wendelinus Mathias Marie Terstappen - Huntingdon Valley PA, US

G01N 33/574

435 723

Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (IGF-1R) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. Test kits that facilitate the detection, enumeration and analysis of such circulating tumor cells are also provided.

2009019, Jul 30, 2009

Dec 22, 2007

12/004805

Mark Carle Connelly - Doylestown PA, US
Gerald V. Doyle - Radnor PA, US
Galla Chandra Rao - Princeton Junction NJ, US
Leon W.M.M. Terstappen - Amsterdam, NL

A01N 1/02, C12Q 1/02

435 2, 435 29

A method for assessing cancer in test subjects is described based upon enumeration of circulating endothelial cells and/or disseminated tumor cells in a test subject. This method is used to quantify disseminated tumor cells. Correlations with circulating tumor cells provides prognostic information with high accuracy in assessing the risk of recurrence in patients with primary breast cancer.

5422277, Jun 6, 1995

Mar 27, 1992

7/859212

Mark C. Connelly - Doylestown PA
Utpal R. Chakraborty - Flemington NJ
Houston G. Brooks - Somerset NJ

Ortho Diagnostic Systems Inc. - Raritan NJ

G01N 3100, G01N 100, C12Q 102

436 10

A cell fixative composition for fixing the internal components of a cell without disrupting the cell surface components is disclosed. The composition contains a compound for preserving intracellular morphology, a compound for fixing internal components of the cell, a compound which facilitates transportation of components across the cellular membrane, and a compound for increasing permeability of cell membranes. Methods for analyzing cells which have been fixed using the composition are also disclosed.